Holen Sie sich die Stockscreener-App
5.795
2.53%
-0.155
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Candel Therapeutics Insider Ups Holding By 22% During Year - simplywall.st
Candel Therapeutics Advances with Promising Cancer Therapies - TipRanks
Bullish Candlestick Pattern Forms in Candel Therapeutics Inc.Price Action & AI Driven Price Predictions - classian.co.kr
Candel Therapeutics Posts Q2 2025 Loss, But History Suggests Strong Post-Earnings Recovery Potential - AInvest
Candel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer Treatment - MSN
Candel Therapeutics Posts Loss in Q2 2025; Surprising Market Resilience Sparks Investor Interest - AInvest
Candel Therapeutics secures RMAT for prostate cancer – ICYMI - Proactive financial news
Candel Therapeutics reports Q2 EPS (9c) vs. (74c) last year - MSN
Candel Therapeutics Inc. Matches Institutional Buying Filter2025 Market Outlook & Long-Term Investment Growth Plans - newsyoung.net
Candel Therapeutics: Promising Pipeline Developments and Strategic Advancements Support Buy Rating - TipRanks
Candel eyes 2026 U.S. filing for CAN-2409 after Phase 3 success and FDA RMAT status - Proactive financial news
Candel Therapeutics’ CAN-2409: Promising Phase 3 Results and Market Potential - TipRanks
Candel Therapeutics shares fall 5.16% intraday despite positive clinical trial results and regulatory designations. - AInvest
Candel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Small cap wrap: Lancaster Resources, Candel Therapeutics, atai Life Sciences, Charbone Hydrogen... - Proactive financial news
Candel Therapeutics sees cash runway into 1Q27 - TipRanks
CCORF Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
Candel Therapeutics Advances Prostate Cancer Therapy Filing After Successful Trial - AInvest
Candel Therapeutics advances toward prostate cancer therapy filing after trial success - Proactive financial news
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Candel Therapeutics, Inc. SEC 10-Q Report - TradingView
Candel's Prostate Cancer Treatment Secures FDA Fast Track After Breakthrough Trial Results - Stock Titan
Can Candel Therapeutics Inc. be recession proofJuly 2025 Sentiment & Low Drawdown Investment Strategies - classian.co.kr
Can Candel Therapeutics Inc. grow without dilutionWeekly Gains Report & Long Hold Capital Preservation Plans - newsyoung.net
Candel Therapeutics Inc. Stages Intraday Comeback — Trend ChangeReal Trader Watchlist of Hot Stocks Released - beatles.ru
Candel Therapeutics CADL 2025Q2 Earnings Preview Downside Ahead on Lack of Revenue Data - AInvest
Cancer Vaccines Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - The Globe and Mail
Candel Therapeutics Institutional Ownership Soars to 44%: Implications for Stock Price Sensitivity - AInvest
Candel Therapeutics shares fall 2.76% intraday after announcing clinical trial initiation for tecarfarin in dialysis patients. - AInvest
How strong is Candel Therapeutics Inc. company’s balance sheetAchieve explosive financial results today - Jammu Links News
What are the latest earnings results for Candel Therapeutics Inc.Achieve consistent double-digit growth - Jammu Links News
What are Candel Therapeutics Inc. company’s key revenue driversCapitalize on market trends early - Jammu Links News
Is it the right time to buy Candel Therapeutics Inc. stockMaximize profits with strategic stock selection - Jammu Links News
How many analysts rate Candel Therapeutics Inc. as a “Buy”Dynamic investment growth - Jammu Links News
What catalysts could drive Candel Therapeutics Inc. stock higher in 2025Phenomenal returns - Jammu Links News
Candel Therapeutics Inc. Stock Analysis and ForecastUnlock powerful portfolio management tools - Jammu Links News
Is Candel Therapeutics Inc. stock overvalued or undervaluedFree Technical Analysis Support - Jammu Links News
What makes Candel Therapeutics Inc. stock price move sharplyGain the edge with real-time market data - Jammu Links News
Is Candel Therapeutics Inc. a growth stock or a value stockFree Stock Data Feed Backed By Experts - jammulinksnews.com
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - MSN
Applying Wyckoff theory to Candel Therapeutics Inc. stockTop Gaining Picks With Entry Signals Identified - metal.it
Candel Therapeutics CMO Garrett Buys, Sells Shares Amid Company's Market Performance. - AInvest
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Why Candel Therapeutics Inc. stock attracts strong analyst attentionMomentum Based Equity Trading Plans Reviewed - beatles.ru
Candel Therapeutics to share company update at Canaccord Genuity Growth Conference - Proactive financial news
Candel Therapeutics CEO Dr. Tak to Share Cancer Immunotherapy Progress at Major Growth Conference - Stock Titan
Is Candel Therapeutics Inc. Stock a Good Fit for Conservative InvestorsAI Driven Buy Alert Trade Blueprint Released - metal.it
Published on: 2025-07-29 16:45:46 - metal.it
What machine learning models say about Candel Therapeutics Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):